Your browser does not have JavaScript enabled and some parts of this website will not work without it.
アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
私たちはウェブサイトをできるだけ使いやすくするために、クッキーを使用しています。
クッキー・ポリシーでは、使用するクッキーをオプトアウトする方法について説明しています。
クッキーの設定を変更しないままでいる場合、このポリシーに同意しているとみなされます。
Welcome
すでにアカウントをお持ちですか?
あなたの診断法や治療法を発展させるための、カスタム抗体開発およびコマーシャル・パートナーシップ
私たちと共にカスタム・ソリューションを創造する
私たちとパートナーになる
研究のためのサポートとアドバイス
サポートハブを表示
実験のステップごとの詳細
プロトコールを表示
世界中でアブカムが主催する研究会やセミナーの日程、内容、演者など
イベント・カレンダー
すべてのパスウェイを見る
インタラクティブ・パスウェイを見る
最新の情報はこちら.
Jul-2020
Cancer Research UK and Abcam launch custom partnership to accelerate cancer research
Mar-2020
Abcam triumphs with industry award for knockout antibody validation success
Jan-2020
Abcam Expands Cell Engineering Capabilities Through Asset Purchase of Applied StemCell’s Gene Editing Platform and Oncology Product Portfolio
Abcam’s new CRISPR-Cas9 cell lines for target identification, validation and pathway discovery
New JBC manuscript promotes industry-leading best practice guidance on antibody validation via Western blotting
Abcam appoints Michael Baldock as Chief Financial Officer
Abcam announces successful acquisition of Expedeon’s Proteomics and Immunology business, enhancing its conjugation capability
Dec-2019
Abcam and SomaServe announce comprehensive partnership to realise the potential of PolyNaut® ‘bionic’ nanoparticles for delivery to live cells
Abcam Honoured As One Of The UK’s Best Places To Work In 2020; A Glassdoor Employees’ Choice Award Winner
Nov-2019
Abcam delivers outstanding performance in new Biocompare antibody market report
Scientists poised to unlock their understanding of autophagy with new antibody-based insights
Abcam agrees to acquire Expedeon’s Proteomics and Immunology business, expanding offerings into the fast-growing conjugation segment
Abcam and BrickBio announce a partnership to incorporate conjugation-ready sites into recombinant antibodies across Abcam's portfolio
Engineered knockout cell lysates for reproducible proteomic analysis
Jul-2019
Abcam Enters Cell Editing Market Through Acquisition of EdiGene’s Knock-out Cell Lines and Lysates Portfolio
May-2019
New tissue clearing kits and reagents for faster, accurate 3D imaging
Apr-2019
NanoString and Abcam Enter Commercial Partnership to Provide Expanded Menu of Antibodies for GeoMx Digital Spatial Profiler
Mar-2019
Abcam collaborates with Visikol to develop new tools for improved tissue clearing and 3D imaging
Abcam wins the UK-China Business award
Feb-2019
Abcam moves to new purpose-built global headquarters
Dr Michael Weiner wins CiteAb’s 2019 Lifetime achievement award
Jan-2019
Abcam expands custom services capabilities with the acquisition of Calico Biolabs
Abcam and the LouLou Foundation partner to develop key research tools for CDKL5 deficiency disorder
Dec-2018
QIAGEN (Suzhou) and Abcam sign strategic MoU collaboration agreement to co-develop companion diagnostic (CDx) and in vitro diagnostic (IVD) reagents and kits for the Chinese market
Abcam 'Most Admired Company' award
Oct-2018
Abcam appoints Cheri Walker, PhD, as Senior Vice President, Corporate Development
New PBS-only antibodies enable more flexible research
Jul-2018
Abcam Merck collaboration produces new PD-L1 antibody for immuno-oncology research
Jun-2018
Congratulations to Alan Hirzel, winner of European Mediscience Awards Chief Executive of the year award
Apr-2018
Abcam and Shuwen Biotech sign strategic MoU to establish global alliance for companion diagnostic (CDx) kit development
Feb-2018
New CatchPoint® SimpleStep® ELISA fluorescent 90-minute assay
Introducing FirePlex®-HT High-throughput Multiplex Immunoassays – Delivering More Data from Precious Samples
Abcam and Molecular Devices announce strategic collaboration
Jan-2018
Abcam wins another CiteAb award
Abcam signs exclusive license agreement with Roche
Aug-2017
Abcam and TTP Labtech collaborate to develop sol-R reagent kits
Jul-2017
The University of Bath enters licensing agreement with Abcam to develop fluorescent detection probe kit for sugar-damaged proteins
Jun-2017
Abcam announces first international Epigenetics conference in South Korea
Jan-2017
Abcam wins two CiteAb awards
Nov-2016
Abcam wins Best Careers Website at the In-house Recruitment Awards
Jul-2016
New multiplex immunoassays with Firefly® particle technology
Apr-2016
Abcam enables faster drug and biomarker discovery with immunoassay research suite
Feb-2016
Congratulations to Jonathan Milner, winner of CiteAb’s Lifetime achievement award
Nov-2015
Abcam offers direct service to Singapore as part of deepening commitment to Asia-Pacific researchers
Abcam acquires AxioMx to access new growth opportunities and extend antibody leadership
Oct-2015
Abcam’s new anti-PD-L1 antibody enables deeper insights into cancer immunology research
Sep-2015
Abcam raises antibody validation standards to improve quality for life science researchers
Jun-2015
Appointment of Chief Legal Officer and Company Secretary
Abcam launches multiplex miRNA profiling assays
Jan-2015
Abcam signs exclusive partnership agreement with A*STAR's Institute of Molecular and Cell Biology
Dec-2014
Sue Harris appointed as non-Executive Director on Abcam Board
Abcam appoints Yvonne Chien as Chief Digital Officer
Nov-2014
Abcam wins 'Best Use of Digital Media' at Life Science Industry Awards
Sep-2014
Abcam licenses novel Ceefourin inhibitors of multidrug resistance protein 4 from Australia's Children's Cancer Institute
Abcam plc announces appointment of new CEO and Board changes
Abcam and Cell Marque sign global strategic marketing agreement for IVD IHC RabMAb® antibodies
Abcam introduces exclusive range of highly validated antibody conjugates
Jun-2014
Abcam's CEO wins Mediscience award
Mar-2014
Abcam introduces Alexa Fluor® 680/790 secondary antibodies for fluorescent western blotting
Feb-2014
Abcam Announces Winner of 15 Discoveries Contest
Jan-2014
Abcam to open office in Shanghai, China
Dec-2013
Abcam wins 'Most Admired Company' award
Nov-2013
Abcam Introduces Alexa Fluor Secondary Antibodies
Oct-2013
Abcam Named AIM Company of the Year
Sep-2013
Abcam Launches SimpleStep ELISA Kits
Jun-2013
Abcam appoints Alan Hirzel as Chief Marketing Officer
Apr-2013
Abcam Welcomes Students from Cambridge Regional College
Mar-2013
Abcam donates an additional £45,000 to local charities
Dec-2012
Abcam helps contribute to growth of hi-tech sector in Cambridge, UK
Nov-2012
We have reached 100,000 products
Oct-2012
HRH The Duke of York visits Abcam to see the Cambridge Phenomenon in action
Sep-2012
Rabbit monoclonal antibodies, available from Abcam following acquisition of Epitomics
Jan-2012
New range of Biochemicals now available from Abcam
Sep-2011
Abcam acquires Ascent Scientific, a specialist provider of biochemicals
May-2011
Abcam acquires MitoSciences in deal which enhances immunoassay portfolio
Nov-2010
Jonathan Milner wins Entrepreneur of the Year award.
Jul-2010
Abcam's Jonathan Milner wins CEO of the Year
300th employee hired
Mar-2010
Abcam wins 'Business of the Year 2009' at the Business Weekly East of England Awards.
Feb-2010
Abcam founder wins 'CEO of the Year' at Quoted Company Awards 2010
Jan-2010
Abcam and Cambridge Design Partnership develop innovative labeling solution
Oct-2009
Abcam named 'Company of the Year' at 2009 AIM Awards
Jun-2009
Abcam’s expansion continues with its fourth move on the Cambridge Science Park
Nov-2008
Winners of tenth anniversary competition announced
Jul-2008
200th employee hired
May-2008
Licensing deal signed with Tepnel Life Sciences
Mar-2008
Grand setting for Japanese sub-dealer meetings
Nov-2007
Automated system to expand monoclonal production
Abcam and leading antibody producer collaborate to make 12,000 rabbit polyclonals
CLC bio customized software supports Abcam's monoclonal development capability
Jeffrey Iliffe appointed as Chief Financial Officer
May-2007
Same day delivery in Cambridge UK
Mar-2007
Abcam to partner in the EPITRON project
Jan-2007
$2 to Médecins Sans Frontières for every new registration
Jul-2006
Extra Abpoints introduced for first Abreviews
Appointment of Non-Executive Directors
Jun-2006
Winner of Best Newcomer in the European Mediscience awards
May-2006
Better antibodies, faster
Feb-2006
Winner of Private Company of the Year, Business Weekly East of England Business Awards 2005
20,000+ products, 1,300 new lysates, Abpromise stats, Abupdate & news
Jan-2006
Fast Abpromise support, free loading control samples, Abupdate & news
Nov-2005
Search filter, conjugated loading controls, Abupdate & news
Sep-2005
Top forty position, Sunday Times Microsoft Tech Track
May-2005
US office on the move
Apr-2005
Queen's Award at first attempt
More space
Dec-2004
A faster service
Oct-2004
First place in Deloitte's Fast 50
Sep-2004
50th employee hired
Jun-2004
Jim Warwick becomes Managing Director (Abcam Ltd)
Feb-2004
Collaboration deal struck with Purely Proteins
Jan-2004
A New Year's Honour
Dec-2003
High growth status recognised again, this time nationally
Oct-2003
Success in Deloitte's Regional Technology Fast 50
Sep-2003
Top twenty position, Sunday Times Arm Tech Track
Jul-2003
British royalty visits Abcam
May-2003
First overseas office established
Apr-2003
Jim Warwick (Technical Director) becomes full-time
Mar-2003
CEN Business Excellence Awards winner
25th employee hired
Feb-2003
On the move again
Nov-2002
Deloitte Top 50 regional winner
Aug-2002
FedEx tie-up boosts customer support services
Jun-2001
Technical Director appointed
May-2001
UK Online for Business Award, highly commended
Oct-2000
CEN Millennium Business Excellence Awards finalist
May-2000
10th employee hired
Apr-2000
Finance Director appointed
Mar-2000
New premises on the Cambridge Science Park
Oct-1999
First (of many) awards
Oct-1998
Open for business